CARsgen Therapeutics Holdings Ltd
HKEX:2171

Watchlist Manager
CARsgen Therapeutics Holdings Ltd Logo
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Watchlist
Price: 9.25 HKD -1.39% Market Closed
Market Cap: 5.3B HKD

CARsgen Therapeutics Holdings Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CARsgen Therapeutics Holdings Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Current Portion of Long-Term Debt
ÂĄ14.8m
CAGR 3-Years
-42%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Current Portion of Long-Term Debt
ÂĄ358.8m
CAGR 3-Years
57%
CAGR 5-Years
43%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Current Portion of Long-Term Debt
ÂĄ1B
CAGR 3-Years
38%
CAGR 5-Years
124%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Current Portion of Long-Term Debt
ÂĄ13.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Current Portion of Long-Term Debt
ÂĄ61.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Current Portion of Long-Term Debt
ÂĄ15m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

CARsgen Therapeutics Holdings Ltd
Glance View

Market Cap
5.3B HKD
Industry
Biotechnology

CARsgen Therapeutics Holdings Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of CAR-T cell therapies. The company is headquartered in Shanghai, Shanghai and currently employs 573 full-time employees. The company went IPO on 2021-06-18. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The firm have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The firm conducts its businesses in China and the United States.

Intrinsic Value
14.11 HKD
Undervaluation 34%
Intrinsic Value
Price

See Also

What is CARsgen Therapeutics Holdings Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
14.8m CNY

Based on the financial report for Dec 31, 2023, CARsgen Therapeutics Holdings Ltd's Current Portion of Long-Term Debt amounts to 14.8m CNY.

What is CARsgen Therapeutics Holdings Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
-42%

Over the last year, the Current Portion of Long-Term Debt growth was -33%. The average annual Current Portion of Long-Term Debt growth rates for CARsgen Therapeutics Holdings Ltd have been -42% over the past three years .

Back to Top